Research and Development (R&D) in the Pharmaceutical Sector: advances, limitations, selectivity, and neglect

João Stacciarini

No xknb5_v1, SocArXiv from Center for Open Science

Abstract: In order to contribute to the studies and debates on the Research and Development (R&D) process in the pharmaceutical sector, this paper conducted an extensive collection, organization, and analysis of data on the topic, exploring the advances, limitations, selectivity, and neglect in this area. It was revealed that the pharmaceutical sector is the second largest investor in R&D, with global expenditures of $238 billion in 2021. The pursuit of profits from successful drugs has driven significant growth in the number of pharmaceutical companies focused on R&D, resulting in 5,416 corporations testing over 20,000 drugs in various phases of research and development. However, this study also points to the limitations of products derived from pharmaceutical R&D, noting that many newly approved drugs do not present significant advantages over existing ones and tend to prioritize maintaining profitable franchises or market competition over population well-being. Furthermore, the selectivity and neglect in R&D investments are highlighted, with certain diseases receiving more attention due to a variety of interests, including socioeconomic aspects.

Date: 2024-08-06
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://osf.io/download/67a3d17e88938905feaf42f6/

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:osf:socarx:xknb5_v1

DOI: 10.31219/osf.io/xknb5_v1

Access Statistics for this paper

More papers in SocArXiv from Center for Open Science
Bibliographic data for series maintained by OSF ().